<DOC>
	<DOCNO>NCT02678312</DOCNO>
	<brief_summary>This study consist two part ( Part 1 Part 2 ) . The purpose Part 1 evaluate way body absorbs , distribute remove drug LCZ696 . This help determine proper dose LCZ696 Part 2 study . The purpose Part 2 compare effectiveness safety LCZ696 enalapril pediatric heart failure patient 52 week treatment .</brief_summary>
	<brief_title>Study Evaluate Safety , Tolerability , Pharmacokinetics Pharmacodynamics LCZ696 Followed 52-week Study LCZ696 Compared With Enalapril Pediatric Patients With Heart Failure</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Enalapril</mesh_term>
	<mesh_term>Enalaprilat</mesh_term>
	<mesh_term>LCZ 696</mesh_term>
	<criteria>Key Chronic heart failure result leave ventricular systolic dysfunction , receive chronic HF therapy ( newly diagnose ) NYHA classification IIIV ( old child : 6 &lt; 18 year old ) Ross CHF classification IIIV ( young child : &lt; 6 year old ) Systemic leave ventricular ejection fraction ≤ 40 % fractional shortening ≤20 % For Part 1 study : Patients must treat ACEI ARB prior screen . Patients Group 1 2 must currently treat dose equivalent least enalapril 0.2 mg/kg prior LCZ696 3.1 mg/kg administration . Group 3 patient participate LCZ696 0.8 mg/kg LCZ696 3.1 mg/kg . Biventricular physiology systemic leave ventricle Key Patient single ventricle systemic right ventricle Patients list heart transplantation ( United Network Organ Sharing status 1A ) hospitalize wait transplant ( inotropes ventricular assist device ) Sustained symptomatic dysrhythmias uncontrolled drug device therapy Patients cardiovascular surgery percutaneous intervention palliate correct congenital cardiovascular malformation within 3 month screen visit . Patients anticipated undergo corrective heart surgery 12 month entry Part 2 Patients unoperated obstructive severe regurgitant valvular ( aortic , pulmonary , tricuspid ) disease , significant systemic ventricular outflow obstruction aortic arch obstruction Patients restrictive hypertrophic cardiomyopathy Active myocarditis Renal vascular hypertension ( include renal artery stenosis ) Moderateto severe obstructive pulmonary disease Serum potassium &gt; 5.3 mmol/L History angioedema Allergy hypersensitivity ACEI / ARB</criteria>
	<gender>All</gender>
	<minimum_age>1 Month</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Pediatric Heart failure ,</keyword>
	<keyword>systemic leave ventricle ,</keyword>
	<keyword>reduce ejection fraction</keyword>
</DOC>